Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia
Sanofi makes AI play, putting up $100M and billions in [...]
Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs
Amgen chooses Generate in $1.9B biobucks deal to churn out [...]
Sanofi tears up Sangamo cell therapy deal in pivot to off-the-shelf approaches
Sanofi tears up Sangamo cell therapy deal in pivot to [...]
Novartis taps Alnylam for ambitious push to fix liver function
Novartis taps Alnylam for ambitious push to fix liver function [...]
VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing up work on eye and liver diseases
VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing [...]
Intellia bags option on autoimmune CAR-T prospect, handing Kyverna rights to use CRISPR tech to create off-the-shelf cell therapy
Intellia bags option on autoimmune CAR-T prospect, handing Kyverna rights [...]
Exelixis nabs Merck veteran as chief medical officer on quest to expand its R&D footprint
Exelixis nabs Merck veteran as chief medical officer on quest [...]
Transatlantic VC veterans tap Novo Holdings to raise $124M rare disease fund
Transatlantic VC veterans tap Novo Holdings to raise $124M rare [...]
With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies
With $415M on the line, Genmab taps Synaffix for antibody-drug [...]
AstraZeneca taps Ionis to join crowd of companies gunning for rare heart disease in deal worth billions in biobucks
AstraZeneca taps Ionis to join crowd of companies gunning for [...]